Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence
Reexamination Certificate
2008-07-25
2011-12-20
Huff, Sheela J (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
8 to 10 amino acid residues in defined sequence
C530S327000, C530S326000, C530S325000, C530S324000
Reexamination Certificate
active
08080634
ABSTRACT:
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells which can be used in vaccine compositions for eliciting anti-tumor immune responses.
REFERENCES:
patent: 6531447 (2003-03-01), Ruben et al.
patent: 7396904 (2008-07-01), Weinschenk et al.
patent: 2009/0004213 (2009-01-01), Singh et al.
patent: 54733 (2001-08-01), None
patent: 59609 (2002-08-01), None
patent: 02078524 (2002-10-01), None
patent: 03000113 (2003-01-01), None
patent: 2004030615 (2004-04-01), None
patent: 2005044990 (2005-05-01), None
patent: 2005116051 (2005-12-01), None
patent: 2007028574 (2007-03-01), None
Essell (J. NIH Res. 1995 7:46).
Spitler (Cancer Biotherapy, 1995, 10:1-3).
Boon (Adv. Can. Res. 1992 58:177-210).
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
Gura (Science, 1997, 278:1041-1042).
Jain (Sci. Am., 1994, 271:58-65).
Written Opinion of PCT/EP2008/006153 Dated Aug. 21, 2009.
Database Uniprot [Online]: Q4TE80-TETNG, “Full=Chromosome Undertermined SCAF5582, Whole Genome Shotgun Sequence”, Jul. 19, 2005. Whitehead Institute Center for Genome Research.
Database GENESEQP [Online]:ABP64001, Leach, MD et al. “New Polypeptide Designated ORFX are Present in Human Atherogenic Cells and are Useful to Preven and Treat OFRX-associated Disorders Including Cancer, Allergy, Wouldn Healing or Autoimmune, Cardiovascular or Inflammatory Disease” Nov. 4, 2002.
McDevitt H., “Specific antigen vaccination to treat autoimmune disease,” PNAS, Oct. 5, 2004, vol. 101, pp. 14627-14630.
Mihalyo et al., “In Vivo Cyclophosphamide and IL-2 Treatment Impedes Self-Antigen-Induced Effector CD4 Cell Tolerization: Implications for Adoptive Immunotherapy,” J. Immunol, 2004, pp. 5338-5345.
Oehlen et al., “Expression of a Tolerizing Tumor Antigen in Peripheral Tissue Does Not Preclude of High-Affinity CD8+ T Cells or CTL Immunotherapy of Tumors Expressing the Antigen,” J. Immunol, 2001, pp. 2863-2870.
Adler A., “Peripheral Tolerization of Effector and Memory T Cells: Implications for Autoimmunity and Tumor-Immunity,” Curr Immunol Rev., Jan. 1, 2005, 1(1) pp. 21-28.
Vella et al., “B cells are not essential for peripheral T-cell tolerance,” Proc. Natl. Acad. Sci, Jan. 1996, vol. 93, pp. 951-955.
Vidard et al., “Specific T-cell tolerance may be preceded by a primary response,” Proc. Natl. Acad. Sci., Jun. 1994, vol. 91, pp. 5627-5631.
Sadovnikova et al., “Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: Reagents for tumor immunotherapy,” Proc. Natl. Acad. Sci., Nov. 1996, vol. 93, pp. 13114-13118.
Kurts et al., “CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose,” PNAS, Oct. 26, 1999, vol. 96, No. 22, pp. 12703-12707.
Polymenidou et al., “Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection,” PNAS, Oct. 5, 2004, vol. 101, pp. 14670-14676.
Maeda et al., “Suppressor T cells regulate the nonanergic cell population that remains after peripheral tolerance is induced . . . ,” PNAS, Nov. 21, 2000, vol. 97, No. 24, pp. 13257-13262.
“Approved Drugs for Oncology,” Center Watch: Oncology Approved Drug Therapies, retrieved from the WWW on Sep. 10, 2010, pp. 1-8 (http://www.centerwatch.com/drug-information/fda-approvals/drug-areas.aspx? AreaID=12).
A search of the National Institutes of Health's (“NIH”) clinicaltrials.gov website on Aug. 23, 2010 for the terms “cancer” and “peptide vaccine” discloses 74 clinical trials that were first received by the NIH between Jan. 1, 1996 and Jul. 27, 2007, 5 pages.
“FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer,” Dendreon Press Release, Apr. 29, 2010, pp. 1-3.
Data from the NIH's clinicaltrials.gov website, clinical trials for Provenge®, 2001, 5 pages.
Database GENESEQ [Online] Nov. 7, 2001, “Novel Signal Transduction Pathway Protein, SEQ ID 642.” XP002497882 Retrieved From EBI Accession No. GSP: AAU17077 Database Accession No. AAU17077, The Whole Document.
Database UNIPROT [Online] Sep. 13, 2005, “Subname: Full=FERMT1 PROTEI;” XP002497883, Retrieved From EBI Accession No. UNIPROT: Q49AC8, Database Accession No. Q49AC8, The Whole Document.
Database GENESEQ [Online], Sep. 3, 2001, “Human Colon Cancer Antigen Protein SEQ ID No. 6503.” XP002505842, Retrieved From EBI Accession No. GSP: AAG75739, Database Accession No. AAG75739, The Whole Document.
Database UNIPROT [Online], May 1, 2000, “Recname: Full=NADPH Oxidase 1; Short=NOX-1; EC=<AHREF=” Http://SRS.EBI.AC.UK/SRSBIN/CGI-BIN/WGETZ?[ENZYME-ECNUMBER:1.*.*.*]+-E >1.-.-.-</A>; Altname: Full=NOH-1; Alt Name: Full=NADH/NADPH Mitogenic Oxidase Subunit P65-MOX; Altname: Full=Mitogenic Oxidase1; Short=MOX1; XP002505848, Retrieved From EBI Accession No. UNIPROT: Q9Y5S8 Database Accession No. Q9Y5S8, The Whole Document.
Database GENESEQ [Online], Jan. 29, 2003, “Human Expressed Protein Tag (EPT) #29.” XP002505843 Retrieved From EBI Accession No. GSP: ABU03249, Database Accesion No. ABU03249 Discloses Sequence 29 of WO02078524. The Whole Document.
Database UNIPROT [Online] Oct. 1, 1989, “Recname: Full=Proliferating Cell Nuclear Antigen; Short=PCNA; Altname: Full=Cyclin;” XP002505844, Retrieved From EBI Accession No. UNIPROT: p12004, Database Accession No. P12004, Comprises Present Sequence 3. The Whole Document.
Database GENESEQ [Online], Nov. 14, 2004, “Tumour-Associated Antigenic Target (TAT) Polypeptide PR080966, SEQ: 1080.” XP002505845, Retrieved From EBI Accession No. GSP: ABM80429. Database Accession No. ABM80429 Discloses Sequence 1080 of WO2004030615. The Whole Document.
Database UNIPROT[Online], Jul. 1, 1993, “Recname: Full-DNA Topoisomerase 2-Beta; EC=<A HREF=”Http://SRS.EBI.SC.UK/SRSBIN/CGI-BIN/WGETZ?[Enzyme-ECNumber:5.99.1.3</A>; Altname: Full=DNA Topoisomerase II, Beta Isozyme; XP002505846, Retrieved From EBI Accession No. UNIPROT:Q02880 Database Accession No. Q02880. The Whole Document.
Database UNIPROT [Online], “Recname: Full-DNA Topoisomerase 2-Alpha; EC=<A HREF=”Http://SRS.EBI.SC.UK/SRSBIN/CGI-BIN/WGETZ?[Enzyme-ECNumber:5.99.1.3]+-E>5.99.1.3.</A>; Altname: Full=DNA Topoisomerase II, Alpha Isozyme; XP002505847, Retrieved From EBI Accession No. UNIPROT P11388; Database Accession No. P11388. The Whole Document, 1989.
Search Report for PCT/EP2008/006153; Dated Jan. 19, 2009.
Hilf Norbert
Lemmel Claudia
Schoor Oliver
Singh Harpreet
Walter Steffen
Baker Donelson Bearman Caldwell & Berkowitz PC
Huff Sheela J
Immatics Biotechnologies GmbH
LandOfFree
Immunogenic epitope for immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic epitope for immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic epitope for immunotherapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4266939